U.S. markets open in 4 hours 3 minutes

Immatics N.V. (IMTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.50+0.29 (+3.15%)
At close: 04:00PM EDT
9.50 0.00 (0.00%)
After hours: 04:00PM EDT

Immatics N.V.

Paul-Ehrlich-Strasse 15
Tübingen 72076
49 7071 5397 0

Full Time Employees388

Key Executives

NameTitlePayExercisedYear Born
Dr. Harpreet Singh Ph.D.CEO, MD, Member of Management Board & Supervisory DirectorN/AN/A1975
Dr. Hans-Georg Rammensee Ph.D.Co-Founder & Member of the Scientific Advisory BoardN/AN/AN/A
Dr. Toni Weinschenk Ph.D.Co-Founder & Chief Innovation OfficerN/AN/A1973
Mr. Arnd Christ MBAChief Financial OfficerN/AN/A1966
Mr. Steffen Walter Ph.D.Chief Technology OfficerN/AN/A1976
Mr. Edward A. SturchioGen. Counsel & Sec.N/AN/AN/A
Ms. Anja Heuer B.Sc.Director of Corp. CommunicationsN/AN/AN/A
Ms. Tamara Louw M.B.A., P.H.R.Sr. Director of HRN/AN/AN/A
Dr. Carsten Reinhardt M.D., Ph.D.Chief Devel. OfficerN/AN/A1967
Dr. Rainer Kramer Ph.D.Chief Bus. Officer & Site Head MunichN/AN/A1965
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Corporate Governance

Immatics N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.